We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that
roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin …

[2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylp urine](roscovitine) is a
potent and selective inhibitor of cyclin-dependent kinases cdc2 and cdk2. In this study, we …

Roscovitine (ROSC), a selective blocker of cyclin‐dependent kinases (CDKs) efficiently
inhibits proliferation of exponentially growing human MCF‐7 breast cancer cells by induction …

Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Frequent deregulation of cyclin-dependent kinase (CDK) activation associated with loss of
cell cycle control was found in most of human cancers. A recent development of a new class …

Roscovitine has been shown to induce the accumulation of the tumor suppressor p53, to
arrest cells in the G1 and G2/M phases of the cell cycle, and to induce apoptosis in human …

Human MCF-7 breast cancer cells are relatively resistant to anti-cancer drugs. Recently, we
reported that roscovitine (ROSC), a selective cyclin-dependent kinase (CDK) inhibitor …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

The deoxyadenosine-resistant mouse leukemia L1210 cell line (Y8) has previously been
shown to have phenotypic differences that appear to be unrelated to the altered properties …

The aim of this study was to compare the effect of two related CDK inhibitors: roscovitine
(ROSC) and olomoucine (OLO) on the cell cycle progression in human breast cancer MCF-7 …